Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | DUT | P33316 | 6/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917968 | 0.92 | TYMP (0.40) | TYMPDUTSLC6A1SLC6A11P2RY14 | |
| SCHEMBL6363039 | 0.79 | TYMP (0.40) | TYMPDUTSLC6A1SLC6A11P2RY14 | |
| SCHEMBL8209464 | 0.72 | P2RY6 (0.54) | TYMPP2RY14 | |
| SCHEMBL8210400 | 0.72 | P2RY6 (0.54) | TYMPP2RY14 | |
| SCHEMBL779246 | 0.72 | TYMP (0.40) | TYMPDUTSLC6A1SLC6A11P2RY14 | |
| SCHEMBL21905172 | 0.72 | TYMP (0.45) | TYMPDUTP2RY14 | |
| SCHEMBL13589363 | 0.72 | TYMP (0.53) | TYMPP2RY14 | |
| SCHEMBL19185368 | 0.72 | CYP3A4 (0.52) | TYMPDUTP2RY14 | |
| SCHEMBL17737292 | 0.72 | CYP3A4 (0.52) | TYMPDUTP2RY14 | |
| SCHEMBL4387787 | 0.72 | TYMP (0.53) | TYMPP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | TYMP 183/4885DUT 5/4885SLC6A1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.